Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy (original) (raw)

• Bao S, Wu Q, Sathornsumetee S et al (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843–7848
  Article PubMed CAS Google Scholar
• Bello L, Carrabba G, Giussani C et al (2001) Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61:7501–7506
  PubMed CAS Google Scholar
• Brockmann MA, Papadimitriou A, Brandt M et al (2003a) Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res 9:4578–4585
  PubMed CAS Google Scholar
• Brockmann MA, Ulbricht U, Gruner K et al (2003b) Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 52:1391–1399 (discussion 1399)
  Article PubMed Google Scholar
• Brockmann MA, Giese A, Mueller K et al (2007) Preoperative thrombocytosis predicts poor survival in patients with glioblastoma efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. Neuro Oncol 9:335–342
  Article PubMed Google Scholar
• Browder T, Butterfield CE, Kraling BM et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886
  PubMed CAS Google Scholar
• Burger PC, Dubois PJ, Schold SC Jr et al (1983) Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58:159–169
  Article PubMed CAS Google Scholar
• Chang EL, Akyurek S, Avalos T et al (2007) Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 68:144–150
  PubMed Google Scholar
• Chi A, Norden AD, Wen PY (2007) Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 7:1537–1560
  Article PubMed CAS Google Scholar
• Coras R, Holsken A, Seufert S et al (2007) The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Mol Cancer Ther 6:1745–1754
  Article PubMed CAS Google Scholar
• Eberhard A, Kahlert S, Goede V et al (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60:1388–1393
  PubMed CAS Google Scholar
• Folkins C, Man S, Xu P et al (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67:3560–3564
  Article PubMed CAS Google Scholar
• Gately S, Kerbel R (2001) Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 7:427–436
  PubMed CAS Google Scholar
• Ghiringhelli F, Menard C, Puig PE et al (2007) Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641–648
  Article PubMed CAS Google Scholar
• Giese A, Kucinski T, Knopp U et al (2004) Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 66:351–360
  Article PubMed Google Scholar
• Grobholz R, Bohrer MH, Siegsmund M et al (2000) Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol Res Pract 196:277–284
  PubMed CAS Google Scholar
• Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045–1047
  Article PubMed CAS Google Scholar
• Hochberg FH, Pruitt A (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30:907–911
  PubMed CAS Google Scholar
• Holash J, Maisonpierre PC, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998
  Article PubMed CAS Google Scholar
• Juni P, Nartey L, Reichenbach S et al (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029
  Article PubMed CAS Google Scholar
• Kakeji Y, Teicher BA (1997) Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 15:39–48
  Article PubMed CAS Google Scholar
• Kang MK, Kang SK (2007) Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 16:837–847
  Article PubMed CAS Google Scholar
• Kelly PJ, Daumas-Duport C, Kispert DB et al (1987) Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 66:865–874
  Article PubMed CAS Google Scholar
• Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423–436
  Article PubMed CAS Google Scholar
• Klement G, Baruchel S, Rak J et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15–R24
  Article PubMed CAS Google Scholar
• Klement G, Huang P, Mayer B et al (2002) Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8:221–232
  PubMed CAS Google Scholar
• Kunkel P, Ulbricht U, Bohlen P et al (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624–6628
  PubMed CAS Google Scholar
• Lamszus K, Brockmann MA, Eckerich C et al (2005) Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 11:4934–4940
  Article PubMed CAS Google Scholar
• Maity A, Pore N, Lee J et al (2000) Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 60:5879–5886
  PubMed CAS Google Scholar
• Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787
  Article PubMed CAS Google Scholar
• Oppitz U, Maessen D, Zunterer H et al (1999) 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol 53:53–57
  Article PubMed CAS Google Scholar
• Pennacchietti S, Michieli P, Galluzzo M et al (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347–361
  Article PubMed Google Scholar
• Reardon DA, Rich JN, Friedman HS et al (2006) Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24:1253–1265
  Article PubMed CAS Google Scholar
• Rijken PF, Bernsen HJ, Peters JP et al (2000) Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 48:571–582
  PubMed CAS Google Scholar
• Scheda A, Finjap JK, Tuettenberg J et al (2007) Efficacy of different regimens of adjuvant radiochemotherapy for treatment of glioblastoma. Tumori 93:31–36
  PubMed CAS Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
  Article PubMed CAS Google Scholar
• Teicher BA, Sotomayor EA, Huang ZD (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702–6704
  PubMed CAS Google Scholar
• Tuettenberg J, Grobholz R, Korn T et al (2005) Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131:31–40
  Article PubMed CAS Google Scholar
• Tuettenberg J, Friedel C, Vajkoczy P (2006) Angiogenesis in malignant glioma—a target for antitumor therapy? Crit Rev Oncol Hematol 59:181–193
  Article PubMed CAS Google Scholar
• Vajkoczy P, Knyazev P, Kunkel A et al (2006) Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 103:5799–5804
  Article PubMed CAS Google Scholar
• Wick W, Platten M, Weller M (2001) Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol 53:177–185
  Article PubMed CAS Google Scholar
• Wick W, Naumann U, Weller M (2006) Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr Pharm Des 12:341–349
  Article PubMed CAS Google Scholar